Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. [electronic resource]
Producer: 19961010Description: 683-93 p. digitalISSN:- 0889-2229
- AIDS Vaccines -- administration & dosage
- Adjuvants, Immunologic -- administration & dosage
- Adolescent
- Adult
- Amino Acid Sequence
- Cells, Cultured
- Consumer Product Safety
- Dose-Response Relationship, Immunologic
- Double-Blind Method
- Female
- HIV Antibodies -- blood
- HIV Envelope Protein gp120 -- immunology
- HIV Infections -- immunology
- HIV-1 -- immunology
- Humans
- Leukocytes, Mononuclear -- cytology
- Male
- Middle Aged
- Molecular Sequence Data
- Polysorbates -- administration & dosage
- Squalene -- administration & dosage
- T-Lymphocytes, Cytotoxic -- immunology
- Vaccines, Synthetic -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.